WALPOLE , MA - AUGUST 6: Estelle Lemieux, a 21-month-old with spinal muscular atrophy, practices ... [+] using her new wheelchair outside of her home in Walpole, MA on Aug. 6, 2019. Estelle will be getting a treatment of Zolgensma after her insurer, Aetna, decided to cover the $2.1 million drug. (Photo by Jessica Rinaldi/The Boston Globe via Getty Images)
The promise of gene therapy is to cure diseases associated with faulty or missing genes. Theres enormous potential. Just this month, at the annual American Society of Hematology meeting, it was shown that gene therapy stops bleeding in hemophilia. Researchers reported that a single injection of a viral-mediated gene therapy vector decreases the bleeding rate among patients with Factor IX-related hemophilia B by 91% over a 6 month period.
Ideally, gene therapies address the root causes of disease with a single curative dose. If they can replace a lifetime of expensive maintenance treatments this may lead to cost savings in the long run. Yet, the high upfront costs, uncertainty surrounding long-term durability, and adverse events have led to some concerns among payers and regulators.
Pharmaceutical firms deploy multiple approaches to pursuing curative gene therapy, including:
These approaches build on advances in basic science. Companies involved in gene therapy research and development include mid-size and large firms. Among other large pharmaceutical firms, Bayer is establishing a cell and gene therapy platform within its pharmaceuticals division. The company aims to deploy the platform in as many indications as possible.
Novel drug development is invariably a risky venture. The issue of risk is further amplified in gene therapy. Promising therapies face unexpected challenges. For example, in a surprise decision this fall, the Food and Drug Administration (FDA) rejected BioMarins license application for its gene therapy to treat severe hemophilia A. According to the FDA, valoctocogene roxaparvovec gene therapy, is not ready for approval in its present form. The FDA changed its data requirements for the application. The agency is now requesting that the sponsor BioMarin provide two years of data from the companys ongoing Phase 3 study of the therapy.
While development challenges will persist, payment hurdles may be equally difficult to overcome. Should many of the gene therapies in the pipeline be approved in the coming decade the budgetary impact burden on payers could become overwhelming. Payer concerns stem in part from there being hundreds of gene therapies in clinical development,across a wide range of therapeutic categories, including among others, cardiovascular disease, Parkinsons, various inherited disorders, different types of cancer, viruses such as HIV, and blood diseases like sickle cell anemia.
The churn or turnover at U.S. insurers - as beneficiaries frequently switch plans - lowers the potential return on investment for payers. So, being saddled with high upfront costs without necessarily experiencing the downstream long-term benefits of gene therapies is a considerable problem for which a structural solution has not yet been found.
The payer assumes all the risk with fixed, static pricing. And, the payer isnt able to properly assess that risk, given that clinical development of gene therapies has, thus far, mostly included only very small numbers of patients. Therefore, the real-world benefits and risks remain unclear at the time of approval. Clearly, given the uncertainties regarding long-term durability of gene therapies as well as the potential for toxicity and other adverse effects to patients, a dynamic pricing structure is not only desirable but essentially required for these treatments.
In what appear to be harbingers of new ways to finance gene therapies and potentially turn fortunes around of therapies lagging in uptake, drug manufacturers are offering - and in some cases payers have been amenable to - indication-specific pricing arrangements, value-based contracts, and installment plans.
For example, in 2018, the FDA approved the gene therapy Luxturna. This treatment holds the promise to restore functional vision to the blind. The sponsor, Spark Therapeutics, set its products price at $425,000 per eye. Harvard Pilgrim entered into a unique outcomes-based contract with Spark Therapeutics. In the deal, Harvard Pilgrim pays for Luxturna, but gets certain refunds if the treatment wears off after a defined period of time. The full details of the contract are confidential. What is known, however, is that because of federal regulations, known as Medicaid best price rules, the maximum refund cannot exceed 23.1%, or the amount Spark Therapeutics is required to offer Medicaid programs. Spark Therapeutics did request that the Centers for Medicare and Medicaid Services (CMS) offer ways to work around the Medicaid best price requirement, in order for it to be able to accept installment payments and provide insurers deeper refunds or rebates in case the product doesnt meet certain targets.
Novartis Gene Therapies has been working closely with payers to create five-year outcomes-based agreements and novel pay-over-time options for the Zolgensma therapy, indicated for spinal muscular atrophy. The sponsor asserts that the treatment is cost-effective, even when priced at $2.125 million per patient. The installment plans would spread out payments over five years. In addition, the sponsor would offer a refund if a patient dies or the treatment otherwise fails within that period.The current alternative to Zolgensma is BiogensSpinraza, which patients take for the duration of their lifetime. The costs of Spinraza are approximately $4 million over a 10-year span.
In 2019, BluebirdBio told investors it was seeking value-based installment plan contracts to reimburse its sickle cell anemia product LentiGlobin for transfusion-dependent beta-thalassemia. The installments would be paid over a period of up to five years.
After an initial charge, Bluebird Bio would only get reimbursed if the one-time infusion benefits patients. This implies that up to 80% of the cost of LentiGlobin would only be made if there is treatment success. And this success would then be measured and tracked in patient registries maintained by payers.
As part of its contracting preparations, Bluebird Bio has sought ways to bypass Medicaid best price rules; for example, waivers to establish an exemption. The company has also pursued a resolution to the issue of portability - when patients change insurers - by way of a mutual recognition strategy across payers.
But, now the FDA wants Bluebird Bio to provide additional information on the manufacturing process it will use as it transitions the product, LentiGlobin, from clinical trials to commercial production. This will push back the timing of execution of contracts until LentiGlobin gets approved by FDA, which may not be until 2022 or later.
Across the various contract constructs described, payments can be administered in different ways that are not mutually exclusive:
Reimbursement of pharmaceutical products generally happens on a per-unit basis, which spreads out costs over years. But, the cost of a gene therapy is much more concentrated, possibly all upfront in a single payment. Such high upfront one-time costs make it harder for payers to underwrite the risk of full payment for one therapy, let alone the entire range of gene therapies that may be coming to market shortly. Therefore, a combination of installment plans and value-based contracting arrangements will likely be the wave of the future for gene therapy reimbursement.
- Difference Between Ex Vivo and In Vivo Gene Therapy - December 30th, 2022
- Gene therapy: The Potential for Treating Type 1 Diabetes - Healthline - December 30th, 2022
- Gene therapy | Description, Uses, Examples, & Safety Issues - December 30th, 2022
- Cell and gene therapy: Biopharma portfolio strategy | McKinsey - December 30th, 2022
- History of Gene Therapy | Discovery and Evolution - December 30th, 2022
- What is Gene Therapy? | FDA - U.S. Food and Drug Administration - December 30th, 2022
- Gene Therapy Gel Offers New Hope Against Rare Blistering Disease - December 30th, 2022
- Fact Check-mRNA vaccines are distinct from gene therapy ... - Reuters - December 6th, 2022
- New Treatments for Retinitis Pigmentosa - American Academy of ... - December 6th, 2022
- The Era of One-Shot, Multimillion-Dollar Genetic Cures Is Here - WIRED - December 6th, 2022
- Greta Thunberg Says UN Climate Conference Is a Scam and She's Not Attending - November 4th, 2022
- This Deepfake AI Singing Dolly Parton's "Jolene" Is Worryingly Good - November 4th, 2022
- There's Something Strange About How These Stars Are Moving, Scientists Say - November 4th, 2022
- Manslaughter Case Has a Strange Twist: Tesla That Killed Couple Was on Autopilot - November 4th, 2022
- Twitter Working on Plan to Charge Users to Watch Videos - November 4th, 2022
- China Plans to Send Monkeys to Space Station to Have Sex With Each Other - November 4th, 2022
- Elon Musk Meeting With Advertisers, Begging Them Not to Leave Twitter - November 4th, 2022
- NASA Sets Launch Date for Mission to $10 Quintillion Asteroid - November 4th, 2022
- Scientists Found a Way to Control How High Mice Got on Cocaine - November 4th, 2022
- Cats May Be Tampering With Crime Scenes, Scientists Say - November 4th, 2022
- Scientists Use Actual Lunar Soil Sample to Create Rocket Fuel - November 4th, 2022
- Scientists Spot "Stripped, Pulsating Core" of Star Caused By Horrific Accident - November 4th, 2022
- US Gov to Crack Down on "Bossware" That Spies On Employees' Computers - November 4th, 2022
- AOC Says Her Twitter Account Broke After She Made Fun of Elon Musk - November 4th, 2022
- Hackers Just Took Down One of the World's Most Advanced Telescopes - November 4th, 2022
- Huge Drone Swarm to Form Giant Advertisement Over NYC Skyline - November 4th, 2022
- Chinese Spaceplane Releases Mystery Object Into Orbit - November 4th, 2022
- That "Research" About How Smartphones Are Causing Deformed Human Bodies Is SEO Spam, You Idiots - November 4th, 2022
- Jeff Bezos' Housekeeper Says She Had to Climb Out the Window to Use the Bathroom - November 4th, 2022
- Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership - PR Newswire - October 19th, 2022
- Gene therapy can make a real impact on global health but we need equitable access, say experts - World Economic Forum - October 19th, 2022
- Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022 - Managed Healthcare Executive - October 19th, 2022
- Carmine Gets Series A Funding to Develop Non-viral Gene Therapy |... - Cystic Fibrosis News Today - October 19th, 2022
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 19th, 2022
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 19th, 2022
- Survey Reveals Most People with Spinal Muscular Atrophy Using New Gene Therapies, Focused on Treatment Pipeline - PR Newswire - October 19th, 2022
- GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies - Yahoo Finance - October 19th, 2022
- Gamma Biosciences, Lonza Enter Cell and Gene Therapy Alliance - Contract Pharma - October 19th, 2022
- Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene... - October 19th, 2022
- Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss(1) - Canada NewsWire - October 19th, 2022
- A sound approach for effective gene therapy delivery to brain - The Source - Washington University in St. Louis - Washington University in St. Louis - October 19th, 2022
- Worldwide AAV Vector Industry Report 2022 - by Type of Therapy, Type of Gene Delivery Method Used, Target Therapeutic Area, Application Area, Scale of... - October 19th, 2022
- LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission - BioSpace - October 19th, 2022
- Health News Roundup: Serum Institute to produce Ebola vaccine for use in Uganda outbreak; Eli Lilly to buy gene therapy company Akouos for $487... - October 19th, 2022
- New Pittsburgh biomanufacturing center to accelerate cell and gene therapy innovation - BioPharma-Reporter.com - August 30th, 2022
- Trinity team's new gene therapy shows promise for treating eye condition affecting millions across the globe - Ophthalmology Times - August 30th, 2022
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 30th, 2022
- Defining the Impact of Gene Therapy - Managed Healthcare Executive - August 30th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - August 30th, 2022
- India Gene Therapy Market Research Report 2022: Prospects, Trends, Market Size and Forecasts to 2028 - ResearchAndMarkets.com - Business Wire - August 30th, 2022
- Global Cell and Gene Therapy Market to Surpass US$ 90,984.2 Million by 2030 - Coherent Market Insights - PR Newswire - August 30th, 2022
- Walk Again Or Stop Blindness. How Gene Therapy Is Revolutionizing Medicine - Nation World News - August 30th, 2022
- Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome - BioSpace - August 30th, 2022
- Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire - August 30th, 2022
- Gene therapies for lung cancer identified by international team of scientists - Labiotech.eu - August 30th, 2022
- BioForest is Breaking Out with Innovation, Talent and Investment - BioSpace - August 30th, 2022
- Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio - Yahoo Finance - August 30th, 2022
- An international team sets out to cure genetic heart diseases with one shot - Freethink - August 30th, 2022
- What is the difference between sickle cells and healthy RBCs? - Medical News Today - August 30th, 2022
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials - HDBuzz - August 30th, 2022
- Cell therapy weekly: Kyverna Therapeutics appoints new Senior Vice President - RegMedNet - August 30th, 2022
- GICELL Announces Research Collaboration with HK inno.N for next-generation CAR-NK therapy - BioSpace - August 30th, 2022
- Document: Big Pharma exec: COVID shots are 'gene therapy' - July 8th, 2022
- Gene & Cell Therapy FAQs | ASGCT - American Society of Gene & Cell ... - July 8th, 2022
- Gene therapy - Mayo Clinic - July 8th, 2022
- FDA approves novel gene therapy to treat patients with a rare form of ... - July 8th, 2022
- Adeno-Associated Virus (AAV) as a Vector for Gene Therapy - July 8th, 2022
- Gene therapy: Where the action is for retinal diseases - Modern Retina - July 8th, 2022
- Adverum cuts jobs, restructures to give eye gene therapy another shot - BioPharma Dive - July 8th, 2022
- EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS - Labiotech.eu - July 8th, 2022
- Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA - Business Wire - July 8th, 2022
- TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022" - PR Newswire - July 8th, 2022
- AAVIATE: Gene therapy via suprachoroidal drug delivery may lower treatment burden for patients with AMD - Modern Retina - July 8th, 2022
- Gene Therapy Market is Expected to Grow Revenue up to USD 20 Billion by 2028 Know More with Infinium Global Research - Digital Journal - July 8th, 2022
- Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week - The Motley Fool - July 8th, 2022
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 8th, 2022
- Sio Gene Therapies Inc. (NASDAQ:SIOX) Short Interest Up 33.4% in June - Defense World - July 8th, 2022
- Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy -... - July 8th, 2022
- A look at prospects for the US gene therapy industry - BioPharma-Reporter.com - December 27th, 2021
- Taysha Gene Therapies Added to the ICE Biotechnology Index - BioSpace - December 27th, 2021